November 2024
Empowering Undergraduates: Johns Hopkins BME Design Team Transforms Healthcare Solutions
Biomedical Engineering, Undergraduate Design Team, Healthcare Innovation, Clinical Challenges, Design Principles, Team-Based Projects, Entrepreneurship, Intellectual Property, Regulatory Frameworks
Pharma’s Future at Stake: Trump’s Victory and Its Implications for Drug Pricing Reform
Donald Trump, Kamala Harris, 2024 Presidential Election, Drug Pricing Reform, Inflation Reduction Act, Medicare Price Negotiations, Pharmaceutical Industry, Biopharma.
FDA Mandates Enhanced Safety Warnings for CAR-T Therapies Due to Secondary Cancer Risks
CAR-T therapy, secondary cancers, FDA boxed warnings, T-cell malignancies, BCMA-directed, CD19-directed, autologous CAR T-cell immunotherapies.
Vertex’s CASGEVY Marks Historic Milestone with First Commercial Patient Infusions, Paving the Way for 2025 Launches
CASGEVY, Vertex Pharmaceuticals, gene therapy, sickle cell disease, beta thalassemia, CRISPR/Cas9, FDA approval, commercial patient infusions, 2025 launches.
Nxera Pharma and Antiverse Collaborate to Develop Novel GPCR-Targeted Antibody Therapeutics Using Generative AI
Nxera Pharma, Antiverse, GPCR-targeted antibodies, Generative AI, Antibody therapeutics, Biopharma collaboration
FDA Delays Decision on Merus’ Zenocutuzumab for NRG1+ Lung and Pancreatic Cancer
Zenocutuzumab, NRG1+ cancer, FDA delay, Merus, lung cancer, pancreatic cancer, bispecific antibody.
Beam Therapeutics Reports Promising Early Results in Sickle Cell Disease Base Editing Therapy, Despite Conditioning-Related Fatality
Beam Therapeutics, Sickle Cell Disease, Base Editing, Gene Therapy, BEAM-101, ESCAPE, Conditioning, Patient Death
PrognomiQ Secures $34 Million Funding to Enhance Early Lung Cancer Detection with Multi-Omics Technology
PrognomiQ, lung cancer detection, multi-omics technology, early detection test, funding, series D round
Sanofi’s Rilzabrutinib Shows Promising Results in Phase III Trial for Immune Thrombocytopenia (ITP)
Rilzabrutinib, BTK inhibitor, Immune Thrombocytopenia (ITP), Phase III trial, Sanofi, LUNA 3 study
A Decade of Progress: Immuno-oncology on the Cusp of a New Era
Immuno-oncology, checkpoint inhibitors, bispecific antibodies, cancer treatment, immunotherapy, cancer research, future of cancer care.